Whitehawk Therapeutics (WHWK) Corporate presentation summary

Differentiated science and pipeline momentum

• ADC platform leverages proprietary CPT113 linker-payload and CBCR bioconjugation, targeting validated but less crowded antigens PTK7, MUC16, and SEZ6.

• Multiple clinical programs advancing: HWK-007 and HWK-016 in Phase 1, HWK-206 IND-enabling with Q3 2026 trial start.

• Option agreements and collaborations enable up to 5 new ADCs and 5 bispecific antibodies, supporting pipeline expansion.

• Cash position of $190M as of June 2026, with runway into 2H 2028.

ADC portfolio and clinical progress

• HWK-007 targets PTK7, highly expressed in ~70% of solid tumors; Phase 1a data expected 1H 2027.

• HWK-016 targets membrane-bound MUC16, avoiding circulating CA125; Phase 1a data expected 1H 2027.

• HWK-206 targets SEZ6 with biparatopic binding for SCLC and neuroendocrine tumors; Phase 1 start Q3 2026.

• All programs utilize a next-gen ADC platform with high stability, selective release, and improved therapeutic index.

Platform validation and competitive positioning

• Hangzhou DAC's CD56-directed ADC using CPT113 linker-payload shows promising efficacy and tolerability in SCLC and NSCLC.

• Whitehawk's CBCR process improves DAR, stability, and half-life over prior versions.

• HWK-007, HWK-016, and HWK-206 demonstrate superior preclinical potency, stability, and safety compared to competitors.